The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone

Drug and Alcohol Dependence

Volumn 154, Issue , 2015, Pages 38-45

  Bisaga, Adam ^a   Sullivan, Maria A ^a   Glass, Andrew ^a   Mishlen, Kaitlyn ^a   Pavlicova, Martina ^a   Haney, Margaret ^a   Raby, Wilfrid N ^a   Levin, Frances R ^a   Carpenter, Kenneth M ^a   Mariani, John J ^a   Nunes, Edward V ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Cannabinoid; Dronabinol; Naltrexone; Opiate dependence; Pharmacotherapy trials; Randomized trial; Treatment

Indexed keywords

DRONABINOL; NALTREXONE; PLACEBO; CANNABINOID; DELAYED RELEASE FORMULATION; NARCOTIC ANTAGONIST;

ADULT; ANXIETY; ARTICLE; CANNABIS SMOKING; CHILL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DETOXIFICATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; FACE EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; INSOMNIA; MALE; MOOD CHANGE; NAUSEA; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; WITHDRAWAL SYNDROME; COMBINATION DRUG THERAPY; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE WITHDRAWAL SYNDROME; THERAPEUTIC USE; YOUNG ADULT;

CANNABIS SATIVA;

ADULT; CANNABINOIDS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRONABINOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84938857325     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.05.013     Document Type: Article

References (37)

1. Bedi G., Cooper Z.D., Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict. Biol. 2013, 18:872-881.
2. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethnopharmacol. 2006, 105:1-25.
3. Bisaga A., Sullivan M.A., Glass A., Mishlen K., Carpenter K.M., Mariani J.J., Levin F.R., Nunes E.V. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. J. Subst. Abuse Treat. 2014, 46(5):546-552.
4. Brooks A.C., Comer S.D., Sullivan M.A., Bisaga A., Carpenter K.M., Raby W.M., Yu E., O'Brien C.P., Nunes E.V. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. J. Clin. Psychiatry 2010, 71:1371-1378.
5. Budney A.J., Vandrey R.G., Hughes J.R., Moore B.A., Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007, 86:22-29.
6. CDC CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR 2012, 61:10-13.
7. Church S.H., Rothenberg J.L., Sullivan M.A., Bornstein G., Nunes E.V. Concurrent substance use and outcome in combined behavioral and naltrexone therapy for opiate dependence. Am. J. Drug Alcohol Abuse 2001, 27:441-452.
8. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., Dackis C., O'Brien C.P. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2006, 63:210-218.
9. Epstein D.H., Preston K.L. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction 2003, 98:269-279.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders - patient edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New York, NY 1995.
11. Frederickson R.C., Hewes C.R., Aiken J.W. Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 1976, 199:375-384.
12. Handelsman L., Cochrane K.J., Aronson M.J., Ness R., Rubinstein K.J., Kanof P.D. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 1987, 13:293-308.
13. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Foltin R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl.) 2008, 197:157-168.
14. Haney M., Ward A.S., Comer S.D., Foltin R.W., Fischman M.W. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl.) 1999, 141:385-394.
15. Hser Y.I., Saxon A.J., Huang D., Hasson A., Thomas C., Hillhouse M., Jacobs P., Teruya C., McLaughlin P., Wiest K., Cohen A., Ling W. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2013, 109:79-87.
16. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 377:1506-1513.
17. Levin F.R., Mariani J.J., Brooks D.J., Pavlicova M., Cheng W., Nunes E.V. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011, 116:142-150.
18. Lichtman A.H., Sheikh S.M., Loh H.H., Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J. Pharmacol. Exp. Ther. 2001, 298:1007-1014.
19. Lopez-Moreno J.A., Gonzalez-Cuevas G., Moreno G., Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict. Biol. 2008, 13:160-187.
20. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, CD002207.
21. McGilveray I.J. Pharmacokinetics of cannabinoids. Pain Res. Manag. 2005, 10(Suppl. A):15A-22A.
22. Nunes E.V., Rothenberg J.L., Sullivan M.A., Carpenter K.M., Kleber H.D. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?. Am. J. Drug Alcohol Abuse 2006, 32:503-517.
23. Panlilio L.V., Justinova Z., Goldberg S.R. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol. Ther. 2013, 138:84-102.
24. Parolaro D., Rubino T., Vigano D., Massi P., Guidali C., Realini N. Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr. Drug Targets 2010, 11:393-405.
25. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009, 156:397-411.
26. Raby W.N., Carpenter K.M., Rothenberg J., Brooks A.C., Jiang H., Sullivan M., Bisaga A., Comer S., Nunes E.V. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am. J. Addict. 2009, 18:301-308.
27. Robledo P., Berrendero F., Ozaita A., Maldonado R. Advances in the field of cannabinoid - opioid cross-talk. Addict. Biol. 2008, 13:213-224.
28. SAMHSA An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. ISubstance Abuse and Mental Health Services Administration, SAMHSA Advisory, Rockville, MD 2012.
29. SAMHSA Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD.
30. Scavone J.L., Sterling R.C., Van Bockstaele E.J. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 2013, 248:637-654.
31. Scavone J.L., Sterling R.C., Weinstein S.P., Van Bockstaele E.J. Impact of cannabis use during stabilization on methadone maintenance treatment. Am. J. Addict. 2013, 22:344-351.
32. Serrano A., Parsons L.H. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol. Ther. 2011, 132:215-241.
33. Sigmon S.C., Bisaga A., Nunes E.V., O'Connor P.G., Kosten T., Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am. J. Drug Alcohol Abuse 2012, 38:187-199.
34. Soyka M., Zingg C., Koller G., Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int. J. Neuropsychopharmacol. 2008, 11:641-653.
35. Vela G., Ruiz-Gayo M., Fuentes J.A. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 1995, 34:665-668.
36. Williams J.B. A structured interview guide for the Hamilton Depression Rating Scale. Arch. Gen. Psychiatry 1988, 45:742-747.
37. Yamaguchi T., Hagiwara Y., Tanaka H., Sugiura T., Waku K., Shoyama Y., Watanabe S., Yamamoto T. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res. 2001, 909:121-126.